Abstract
The combination of metformin hydrochloride (MTF) and glipizide (GLZ) is second-line medication for diabetes mellitus type 2 (DMT2). In the present study, elementary osmotic pump(EOP)tablet is designed to deliver the combination of MTF and GLZ in a sustained and synchronized manner. By analyzing different variables of the formulation, sodium hydrogen carbonate is introduced as pH modifier to improve the release of GLZ, while ethyl cellulose acts as release retardant to reduce the burst release phase of MTF. A two factor, three level face-centered central composite design (FCCD) is applied to investigate the impact of different factors on drug release profile. Compared with conventional tablets, the elementary osmotic pump (EOP) tablet demonstrates a controlled release behavior with relative bioavailability of 99.2% for MTF and 99.3% for GLZ. Data also shows EOP tablet is able to release MTF and GLZ in a synchronized and sustained manner both in vitro and in vivo
| Original language | English |
|---|---|
| Journal | Drug Development and Industrial Pharmacy |
| Early online date | 09 Jun 2016 |
| DOIs | |
| Publication status | Early online date - 09 Jun 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Synchronized and sustained release; elementary osmotic pump (EOP); face-centered central composite design; metformin hydrochloride/glipizide
Fingerprint
Dive into the research topics of 'Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery'. Together they form a unique fingerprint.Profiles
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver